Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

Federal documents show he disagreed with conclusions the benefits outweighed the risk of side effects, which are rare.

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

According to a new poll, the subject appears to be less controversial than the loud minority would have us believe.

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to the Centers for Disease Control and Prevention.

The Indian Council of Medical Research (ICMR) conducted extensive studies to study whether there is any connection between ...

showed superior efficacy in a Phase 3 study that compared it with a licensed standard-dose seasonal flu vaccine in adults aged 50 years and older. Moderna said mRNA-1010 achieved the most stringent ...

A new study from the University of Oxford has revealed a surprising benefit of the respiratory syncytial virus (RSV) vaccine: ...

The vaccine panel hand-selected by health secretary and anti-vaccine advocate Robert F. Kennedy Jr. on Thursday voted ...